JP2019515915A - 甲状腺ベータアゴニストの使用 - Google Patents

甲状腺ベータアゴニストの使用 Download PDF

Info

Publication number
JP2019515915A
JP2019515915A JP2018555273A JP2018555273A JP2019515915A JP 2019515915 A JP2019515915 A JP 2019515915A JP 2018555273 A JP2018555273 A JP 2018555273A JP 2018555273 A JP2018555273 A JP 2018555273A JP 2019515915 A JP2019515915 A JP 2019515915A
Authority
JP
Japan
Prior art keywords
optionally substituted
group
alkyl
atoms
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018555273A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515915A5 (https=
Inventor
リアン，ブライアン
ハンレー，ロシェル
ディナーマン，ミシャ
Original Assignee
バイキング セラピューティクス，インコーポレーテッド
バイキング セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイキング セラピューティクス，インコーポレーテッド, バイキング セラピューティクス，インコーポレーテッド filed Critical バイキング セラピューティクス，インコーポレーテッド
Publication of JP2019515915A publication Critical patent/JP2019515915A/ja
Publication of JP2019515915A5 publication Critical patent/JP2019515915A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
JP2018555273A 2016-04-22 2017-04-24 甲状腺ベータアゴニストの使用 Pending JP2019515915A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326431P 2016-04-22 2016-04-22
US62/326,431 2016-04-22
PCT/US2017/029102 WO2017185083A1 (en) 2016-04-22 2017-04-24 Use of thyroid beta-agonists

Publications (2)

Publication Number Publication Date
JP2019515915A true JP2019515915A (ja) 2019-06-13
JP2019515915A5 JP2019515915A5 (https=) 2020-06-11

Family

ID=60117062

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018555273A Pending JP2019515915A (ja) 2016-04-22 2017-04-24 甲状腺ベータアゴニストの使用

Country Status (10)

Country Link
US (1) US20190134069A1 (https=)
EP (1) EP3445372B1 (https=)
JP (1) JP2019515915A (https=)
KR (1) KR102407053B1 (https=)
CN (3) CN110200978B (https=)
AU (2) AU2017252122B2 (https=)
BR (1) BR112018071559B1 (https=)
CA (1) CA3021677C (https=)
MX (1) MX2018012904A (https=)
WO (1) WO2017185083A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3445373B1 (en) 2016-04-22 2024-08-21 Viking Therapeutics, Inc. Use of thyroid beta-agonists
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof
JP2025520449A (ja) * 2022-06-15 2025-07-03 バイキング セラピューティクス，インコーポレーテッド Ｘ－ａｌｄ治療のための甲状腺ベータ作動薬投与計画

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
JP2019507069A (ja) * 2016-02-29 2019-03-14 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ヒンジリッド容器およびブランク

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
DK0999825T3 (da) 1997-07-29 2004-02-09 Alcon Lab Inc Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
CA2534484A1 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2543132A1 (en) * 2003-10-23 2005-05-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
CA2638753A1 (en) * 2004-12-08 2006-06-15 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
EP1987827A1 (en) * 2006-02-20 2008-11-05 Takeda Pharmaceutical Company Limited Novel pharmaceutical
HUE038366T2 (hu) * 2010-08-16 2018-10-29 Allergan Inc Módszer szabályozó T-sejtek alfa-2B adrenerg receptor agonistákkal való aktiválásához
EP3259246B1 (en) * 2015-02-20 2023-03-22 Oregon Health & Science University Derivatives of sobetirome
CN109475121B (zh) * 2016-05-18 2021-06-25 俄勒冈健康科学大学 苏比替罗衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
JP2019507069A (ja) * 2016-02-29 2019-03-14 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ヒンジリッド容器およびブランク

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. STEROID BIOCHEM. MOL. BIOL., vol. 116, no. 1, JPN6021009306, 2009, pages 37 - 43, ISSN: 0004466091 *

Also Published As

Publication number Publication date
AU2017252122A1 (en) 2018-11-15
EP3445372A4 (en) 2020-03-25
KR20190017748A (ko) 2019-02-20
AU2023202321A1 (en) 2023-05-11
CA3021677C (en) 2024-11-12
KR102407053B1 (ko) 2022-06-10
BR112018071559B1 (pt) 2024-02-06
CN113730421A (zh) 2021-12-03
WO2017185083A1 (en) 2017-10-26
CN110200978A (zh) 2019-09-06
US20190134069A1 (en) 2019-05-09
AU2023202321B2 (en) 2025-04-24
AU2017252122B2 (en) 2023-02-09
CA3021677A1 (en) 2017-10-26
CN109641003A (zh) 2019-04-16
EP3445372B1 (en) 2026-02-25
MX2018012904A (es) 2019-01-31
EP3445372A1 (en) 2019-02-27
CN110200978B (zh) 2023-10-31
BR112018071559A2 (pt) 2019-05-14

Similar Documents

Publication Publication Date Title
US12440502B2 (en) Use of thyroid beta-agonists
AU2023202321B2 (en) Use of thyroid beta-agonists
KR20190125432A (ko) 글루타미나제 억제제를 사용하는 병용 요법
JP2017517548A (ja) グルタミナーゼ阻害剤との併用療法
JP7019585B2 (ja) 核酸プロドラッグ
HK40064933A (en) Use of thyroid beta-agonists
HK40013781A (en) Use of thyroid beta-agonists
HK40013781B (zh) 甲状腺β-激动剂的应用
HK40007271A (en) Use of thyroid beta-agonists
CN108289899A (zh) 采用葡萄糖生成的抑制剂的联合疗法
HK1257604A1 (en) Conjoint therapies with inhibitors of glucose production
WO2017127417A1 (en) Phosphopantothenate compounds

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210817